Abiomed's Impella® Technology Showcased at 2017 American College of Cardiology Scientific Session With More Than 10 Presenta...
March 16 2017 - 08:00AM
Abiomed, Inc. (NASDAQ:ABMD), a leading provider of breakthrough
heart support and recovery technologies, announces that there are
more than 10 presentations, including a late-breaking clinical
research presentation, featuring the Impella® line of heart pumps,
in addition to 17 poster presentations scheduled during the
American College of Cardiology’s 66th Annual Scientific Session,
March 17-19 at the Walter E. Washington Convention Center in
Washington, DC.
Abiomed is committed to improving outcomes in Protected PCI and
cardiogenic shock through technology and innovation, excellence in
education, clinical research, and appropriate and standardized use.
The following initiatives are planned for ACC:
- Featured Clinical Research: Outcomes for 15,259
Patients with Acute MI Cardiogenic Shock (AMICS) supported with
Impella devices and early results from
unprecedented collaboration in Detroit On Sunday, March
19th at 2:00 PM, Dr. William O’Neill of Henry Ford Health System
will present new data from the Impella Quality (IQ) Assurance
Program, an initiative designed to improve outcomes in Protected
PCI and cardiogenic shock. One component of the program is
Abiomed's IQ Database, a real-world collection of clinical
information derived from the treatment of patients with Impella
devices over the past eight years. This observational data,
combined with clinical data collected in the cVAD Registry and FDA
pre- and post-market studies, is used to develop clinical protocols
by highlighting the best practices associated with superior,
real-world outcomes.
- Detroit Cardiogenic Shock Initiative (DCSI)
Leveraging best practices and protocols from Abiomed Impella
Quality (IQ) Assurance Program, Dr. O’Neill will share early
results and new data from the Detroit Cardiogenic Shock Initiative
(DCSI), an unprecedented partnership between five competitive
hospital systems in metro Detroit with the goal of determining
whether outcomes in cardiogenic shock can be improved with best
practice protocols, including early use of Impella before PCI.
These protocols are based on data derived from the IQ Database and
top performing hospitals in Detroit.
- Abiomed Booth Activities Abiomed's booth #2427
will feature daily demonstrations and opportunities for physicians
to engage in hands-on simulations of the Impella platform with new
simulator updates. Abiomed’s product specialists will discuss new
technologies and innovations.
- Potential Live Cases Utilizing
Impella Devices Abiomed anticipates the potential
broadcast of several live cases utilizing Impella devices from
participating sites. Further details regarding these live cases
will be announced the day of the scheduled procedures, as patient
status is subject to change.
The schedule for ACC symposia is included below. Additional
Impella-related presentations and poster sessions are anticipated.
The Interventional Toolbox for Complex Higher-Risk (and
Indicated) Patients (CHIP) Marriott Marquis, Marquis
Ballroom, Salon 5, Level M2 Thursday, March 16 | 6:30-9:00 PM
Chairs: Navin K. Kapur, MD William L. Lombardi, MD James M. McCabe,
MD Ajay J. Kirtane, MD, SM
A Changing Approach to Percutaneous Hemodynamic Support:
Decisions, Devices and Results Marriott Marquis, Marquis
Ballroom, Salon 5, Level M2 Saturday, March 18 | 6:15-7:45 AM
Faculty: Navin K. Kapur, MDWilliam O’Neill, MD Ajay
Srivastava, MD Eric Velazquez, MD
ABOUT IMPELLA HEART PUMPS
The Impella 2.5®, Impella CP® and Impella 5.0®
are FDA-approved heart pumps used to treat heart attack patients in
cardiogenic shock, and have the unique ability to enable native
heart recovery, allowing patients to return home with their own
heart. The Impella 2.5 and Impella CP devices are also approved to
treat certain advanced heart failure patients undergoing elective
and urgent percutaneous coronary interventions (PCI) such as
stenting or balloon angioplasty, to re-open blocked coronary
arteries. Abiomed's right-side heart pump, the Impella RP® device,
is approved to treat certain patients experiencing right heart
failure. To learn more about the Impella platform of heart pumps,
including their approved indications and important safety and risk
information associated with the use of the devices, please visit:
www.protectedpci.com.
The ABIOMED logo, ABIOMED, Impella, Impella 2.5, Impella 5.0,
Impella LD, Impella CP, Impella RP, and Recovering Hearts. Saving
Lives. are registered trademarks of ABIOMED, Inc. in the U.S. and
in certain foreign countries.
ABOUT ABIOMED Based in
Danvers, Massachusetts, Abiomed, Inc. is a leading provider of
medical devices that provide circulatory support. Our
products are designed to enable the heart to rest by improving
blood flow and/or performing the pumping of the heart. For
additional information, please visit: www.abiomed.com.
**For further information please contact:
Adrienne Smith
Senior Director, Public Relations and Corporate Communications
978-646-1553
adsmith@abiomed.com
Ingrid Goldberg
Director, Investor Relations
978-646-1590
igoldberg@abiomed.com
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Feb 2024 to Mar 2024
ABIOMED (NASDAQ:ABMD)
Historical Stock Chart
From Mar 2023 to Mar 2024